The Scientific Program - Neuroimmunology
|
Saturday, April 06, 2019 |
|
Hall C- DE FALLA |
|
|
10:45-12:25 |
SESSION 33 | NEUROIMMUNOLOGY: MYASTHENIA GRAVIS (MG) AND APLA SYNDROME |
||
|
Chairpersons: |
|
||
|
10:45-11:35 |
Treatment of refractory MG. Capsule: Although MG is an overall success story in neurologic therapeutics, about 10% of the patients remain symptomatic despite treatments. Recently, Eculizumab , a monoclonal antibody against complement C5, was approved for treating refractory MG. Is such a clinical benefit sufficient to justify its use in considering its excessive cost of $500,000 per year? |
||
|
10:45-10:55 |
Host: Bruno Gran, UK |
||
|
10:55-11:10 |
Yes: Renato Mantegazza, Italy |
||
|
11:10-11:25 |
No: Vivian Drory, Israel |
||
|
11:25-11:35 |
Discussion and rebuttals |
||
|
|
|
||
|
11:35-12:25 |
Should immunotherapy be part of first line treatment in APLA syndrome? |
||
|
|
Capsule: The antiphospholipid syndrome (APS) is formally defined by the presence of high titers of antibodies together with thrombotic arterial and venous events. The mainstay of treatment in patients with neurological manifestations of APS is anticoagulation which rarely affects the levels of the circulating antibodies and has significant risks. Furthermore, many of the neurological manifestations of APS may be due to direct effects of circulating antibodies. It is therefore open to debate whether the treatment of APS should include antibody lowering therapies, as is well established in other humural mediated autoimmune diseases |
||
|
11:35-11:45 |
Host: Abhijit Chaudhuri, UK |
||
|
11:45-12:00 |
Pro: Joab Chapman, Israel |
||
|
12:00-12:15 |
Con: |
||
|
12:15-12:25 |
Discussion and rebuttals |
||
|
|
Lunch Break |
||
|
13:25-15:05 |
SESSION 34 | NEUROMYELITIS OPTICA (NMO): LIMBIC ENCEPHALITIS |
||
|
Chairpersons: |
Rina Aharoni, Israel & Ranko Raicevic, Serbia, |
||
|
13:25-14:15 |
Immunosuppresive/immunomodulating treatment in autoimmune limbic encephalities - when to stop? Based on clinical status or based on lab data? |
||
|
|
Capsule: Antibodies to cell-surface neuronal molecules (eg. LGI1, NMDAR) are diagnostic and causative in forms of autoimmune encephalitis, yet many express doubts about the usefulness of antibody levels during management. Are laboratory assays geared to diagnosis, but not follow-up? Can accurate measurements can be helpful in patient management more than clinical state? |
||
|
13:25-13:35 |
Host: Friedemann Paul, Germany |
||
|
13:35-13:50 |
Clinical state: Jacek Losy, Poland |
||
|
13:50-14:05 |
Lab data: Angela Vincent, UK |
||
|
14:05-14:15 |
Discussion and rebuttals |
||
|
|
|
||
|
14:15-15:05 |
The future of NMO treatment is immune tolerance, not immunosuppression. |
||
|
14:15-14:25 |
Host: Anu Jacob, UK |
||
|
14:25-14:40 |
Pro: Brian Weinshenker, USA |
||
|
14:40-14:55 |
Con: Hans Peter Hartung, Germany |
||
|
14:55-15:05 |
Discussion and rebuttals |
||
|
15:05-15:20 |
Coffee Break |
||
|
15:20-17:00 |
SESSION 35 | NMO: WHEN TO STOP TREATMENT |
||
|
Chairpersons: |
|
||
|
15:20-16:10 |
Should non-steroidal immunosuppression be used in pregnant patients with NMO? |
||
|
|
Capsule: Attacks of NMO continue at the same frequency throughout pregnancy and increase in frequency postpartum; they and other consequences of NMO may have devastating consequences to mother and fetus. Can maintenance immunosuppressive drugs be safely administered or continued throughout pregnancy? Do they mitigate some or all of the consequences of NMO? |
||
|
15:20-15:30 |
Host: Oscar Fernandez, Spain |
||
|
15:30-15:45 |
No: Abhijit Chaudhuri, UK |
||
|
15:45-16:00 |
Yes: Brian Weinshenker, USA |
||
|
16:00-16:10 |
Discussion and rebuttals |
||
|
16:10-17:00 |
Immune suppression treatments can be withheld in NMO patients who have prolonged stability. |
||
|
|
Capsule: Neuromyelitis optica spectrum disorder (NMOSD) is demyelinating disease of the central nervous system which is characterized by episodes of optic neuritis and transverse myelitis. The best treatment approach currently available is attack prevention using immunosuppressive drugs. Unfortunately, not always immunotherapy is successful and has to be changed. However, many patients can be stabilized for the long time. |
||
|
16:10-16:20 |
Host: Brian Weinshenker, USA |
||
|
16:20-16:35 |
Pro: Hans Peter Hartung, Germany |
||
|
16:35-16:50 |
Con: Andrzej Glabinski, Poland |
||
|
16:50-17:00 |
Discussion and rebuttals |
||
|
|
|
||
|
17:00-17:15 |
New players Session Novartis, Migrane |
||
|
17:15-17:30 |
Objective markers for onset of transthyretin familial amyloid polyneuropathy in asymptomatic ser77tyr mutation carriers: Amir Dori, Israel |
||
|
17:30-19:00 |
MS and Neuroimmunology Oral free communications |
||
|
END OF SATURDAY HALL C- DE FALLA |
|||
